EP1998752A2 - Nanoparticule de polylactide - Google Patents

Nanoparticule de polylactide

Info

Publication number
EP1998752A2
EP1998752A2 EP07711937A EP07711937A EP1998752A2 EP 1998752 A2 EP1998752 A2 EP 1998752A2 EP 07711937 A EP07711937 A EP 07711937A EP 07711937 A EP07711937 A EP 07711937A EP 1998752 A2 EP1998752 A2 EP 1998752A2
Authority
EP
European Patent Office
Prior art keywords
agents
nanoparticles
lactide
agent
primary emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07711937A
Other languages
German (de)
English (en)
Inventor
Jörg KREUTER
Svetlana Gelperina
Olga Maksimenko
Alexander Khalanskiy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1998752A2 publication Critical patent/EP1998752A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

La présente invention concerne un système d'alimentation ciblée de substances actives pour l'administration d'une substance pharmacologiquement active sur le système nerveux central d'un mammifère au travers de la barrière hémato-encéphalique, le système d'administration ciblée de médicament comprenant une nanoparticule constituée de poly(DL-lactide) et/ou de poly(DL-lactide-co-glycolide) et d'au moins une substance pharmacologiquement active, absorbée dans la nanoparticule, adsorbée à sa surface ou incorporée dans son volume, et soit contenant du TPGS, soit présentant un revêtement du tensioactif Pluronic 188, qui est isolé sur la particule chargée de substance active. L'invention concerne également un procédé de fabrication du système d'administration ciblée de substances actives et l'utilisation du système pour l'administration ciblée de substances actives pour le traitement d'une maladie ou d'un trouble du système nerveux central.
EP07711937A 2006-03-24 2007-03-13 Nanoparticule de polylactide Withdrawn EP1998752A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006013531A DE102006013531A1 (de) 2006-03-24 2006-03-24 Polylactid-Nanopartikel
PCT/EP2007/002198 WO2007110152A2 (fr) 2006-03-24 2007-03-13 Nanoparticule de polylactide

Publications (1)

Publication Number Publication Date
EP1998752A2 true EP1998752A2 (fr) 2008-12-10

Family

ID=38110479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07711937A Withdrawn EP1998752A2 (fr) 2006-03-24 2007-03-13 Nanoparticule de polylactide

Country Status (14)

Country Link
US (2) US8003128B2 (fr)
EP (1) EP1998752A2 (fr)
JP (1) JP2009530325A (fr)
KR (1) KR20080111079A (fr)
CN (1) CN101410099A (fr)
AU (1) AU2007229738A1 (fr)
BR (1) BRPI0709352A2 (fr)
CA (1) CA2644411A1 (fr)
DE (1) DE102006013531A1 (fr)
IN (1) IN2008DE08036A (fr)
MX (1) MX2008011892A (fr)
NZ (1) NZ571354A (fr)
RU (1) RU2423104C2 (fr)
WO (1) WO2007110152A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111939151A (zh) * 2020-07-04 2020-11-17 浙江工业大学 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
WO2010005725A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d’utilisation associés
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (fr) 2008-12-15 2010-07-01 Bind Biosciences Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques
EP2509634B1 (fr) 2009-12-11 2019-03-06 Pfizer Inc Formulations stables pour particules thérapeutiques de lyophilisation
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US8974691B2 (en) 2010-09-24 2015-03-10 Fujimi Incorporated Composition for polishing and composition for rinsing
JP5687354B2 (ja) * 2010-11-26 2015-03-18 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ 薬物送達デバイス
WO2012135010A2 (fr) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Nanovecteurs synthétiques à libération médiée par voie osmotique
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
ES2656091T3 (es) * 2012-07-27 2018-02-23 Izumi Technology, Llc. Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
ES2732377T3 (es) 2012-09-17 2019-11-22 Pfizer Procedimiento de preparación de nanopartículas terapéuticas
CL2012003209A1 (es) * 2012-11-16 2013-04-19 Univ Santiago Chile Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
BR112016021130A2 (pt) 2014-03-14 2017-08-15 Pfizer Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
CN103893769B (zh) * 2014-04-16 2016-03-23 江西科技师范大学 含聚乙丙交酯靶向高分子药物载体及其制备方法
CN109613177B (zh) * 2014-07-01 2021-08-20 科蒙森斯公司 用于鉴定羊水的诊断组合物
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
HRP20220304T1 (hr) 2015-06-24 2022-05-13 F. Hoffmann - La Roche Ag Anti-transferinska receptorska protutijela s prilagođenim afinitetom
RU2595859C1 (ru) * 2015-07-20 2016-08-27 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Полимеросодержащее лекарственное средство на основе противоопухолевого препарата этопозида
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
RU2606839C1 (ru) * 2015-10-26 2017-01-10 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Лекарственный препарат противотуберкулезного действия на основе D-циклосерина в виде лиофилизата и способ получения лекарственного препарата
RU2649743C1 (ru) * 2016-10-24 2018-04-04 Станислав Анатольевич Кедик Жидкая лекарственная форма, содержащая лекарственное вещество, помещенное в биоразлагаемые полимеры
CN106806352B (zh) * 2017-01-26 2019-01-15 中国人民解放军军事医学科学院毒物药物研究所 一种可缓释、靶向应用于神经退行性疾病的纳米药物
WO2018237004A1 (fr) * 2017-06-20 2018-12-27 University Of Maryland, Baltimore Nanoparticules sélectives chargées de ligand de rary pour la manipulation de la croissance osseuse cible
RU2675810C1 (ru) * 2017-12-19 2018-12-25 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Полимерный комплекс для молекулярно-прицельной терапии и способ его получения
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
CN108395543B (zh) * 2018-05-31 2020-09-22 华南理工大学 一种改性聚轮烷、基于聚轮烷的载药胶束及其制备方法与应用
US20220175687A1 (en) * 2019-04-11 2022-06-09 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3750524A1 (fr) * 2019-06-13 2020-12-16 CAPNOMED GmbH Administration retardée et modifiée de médicaments anti-cancer
EP3750523A1 (fr) * 2019-06-13 2020-12-16 CAPNOMED GmbH Système de distribution de substances actives
RU2734710C1 (ru) * 2019-06-14 2020-10-22 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБТМ ФМБА России) Наночастицы на основе биодеградирующих полимеров с инкапсулированными в них противоопухолевыми препаратами
CN116018401A (zh) * 2020-07-29 2023-04-25 加利福尼亚大学董事会 驱动生肌性干细胞扩增的化学物混合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
WO1995022963A1 (fr) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
WO1998056361A1 (fr) 1997-06-13 1998-12-17 Medinova Medical Consulting Gmbh Systeme de ciblage de medicament, procede permettant de le preparer et son utilisation
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20060024248A1 (en) * 2003-03-23 2006-02-02 Combe Incorporated Composition and method employing membrane structured solid nanoparticles for enhanced delivery of oral care actives
WO2004084871A1 (fr) 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Nanoparticules intraveineuses pour cibler une administration de medicaments et pour une liberation de medicaments prolongee
WO2005003180A2 (fr) * 2003-04-10 2005-01-13 Pr Pharmaceuticals Procede de production de microparticules a base d'emulsion
JP2006528700A (ja) * 2003-05-20 2006-12-21 エリモス・ファーマスーティカルズ・エルエルシー 肥満の治療のためのカテコールブタンの投与のための方法と組成物
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20050084456A1 (en) * 2003-10-21 2005-04-21 Liping Tang Functionalized particles
KR101123520B1 (ko) * 2003-12-04 2012-03-13 디에스엠 아이피 어셋츠 비.브이. 자외선 필터 활성을 갖는 미세캡슐 및 그의 제조방법
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007110152A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111939151A (zh) * 2020-07-04 2020-11-17 浙江工业大学 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用

Also Published As

Publication number Publication date
US20110293730A1 (en) 2011-12-01
WO2007110152A8 (fr) 2007-12-13
US8003128B2 (en) 2011-08-23
IN2008DE08036A (fr) 2009-03-20
RU2423104C2 (ru) 2011-07-10
DE102006013531A1 (de) 2007-09-27
US20090263491A1 (en) 2009-10-22
AU2007229738A1 (en) 2007-10-04
KR20080111079A (ko) 2008-12-22
MX2008011892A (es) 2008-11-14
WO2007110152A3 (fr) 2008-02-21
BRPI0709352A2 (pt) 2011-07-12
CA2644411A1 (fr) 2007-10-04
CN101410099A (zh) 2009-04-15
RU2008140367A (ru) 2010-04-20
JP2009530325A (ja) 2009-08-27
NZ571354A (en) 2011-02-25
WO2007110152A2 (fr) 2007-10-04

Similar Documents

Publication Publication Date Title
EP1998752A2 (fr) Nanoparticule de polylactide
DE60311801T2 (de) Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung
EP1817035B1 (fr) Formulations solides d'agents liquides biologiquement actifs
EP2819659B1 (fr) Procédé de fabrication de nanoparticules chargées d'une substance active
G Nava-Arzaluz et al. Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles
DE60220519T2 (de) Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
CZ377296A3 (en) Stabilized and sterilizably filterable nano particles, process of their preparation and pharmaceutical composition containing thereof
EP2029119A2 (fr) Nanoparticules polymères solides fonctionnalisées pour applications diagnostiques et thérapeutiques
WO2009074274A1 (fr) Nanoparticules polymères solides fonctionnalisées contenant des épothilones
EP2408438A2 (fr) Matériaux composites chargés en produits thérapeutiques et de diagnostics comprenant des nanoparticules polymères et des fibres polymères
CH710313B1 (de) Anti-Tumor-Medikament mit aktivem Targeting und dessen Herstellungsmethode.
CN102099016A (zh) 载药的聚合物纳米微粒及其制备和使用方法
CN101495148A (zh) 包括至少一种抗癌药和至少一种聚合物的药物组合物
JP5425890B2 (ja) 難溶性薬物を含む均一なサイズの高分子ナノ粒子製造方法
CN109381447B (zh) 一种载虾青素磷脂纳米粒及其制备方法与应用
US10172867B2 (en) Afobazole nanoparticles formulation for enhanced therapeutics
US20210106536A1 (en) Drug delivery agents for prevention or treatment of pulmonary disease
WO2012089220A1 (fr) Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé
Domb et al. Lipospheres for controlled delivery of substances
US20230270681A1 (en) Drug delivery agents for prevention or treatment of pulmonary disease
EP2355794B1 (fr) Solutions de substances lipophiles, en particulier solutions de médicament
WO2019048424A1 (fr) Invention concernant des nanparticules contenant des taxanes destinées à une application par inhalation
KR20170114245A (ko) 저분자 메틸셀룰로오스 기반의 비경구 생리활성물질 전달용 조성물
WO2009059989A1 (fr) Émulsions aqueuses contenant un principe actif hydrophobe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080908

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111222